Your browser doesn't support javascript.
Morning vs. evening administration of antiviral therapy in COVID-19 patients. A preliminary retrospective study in Ferrara, Italy.
De Giorgi, A; Fabbian, F; Di Simone, E; Greco, S; De Giorgio, R; Zuliani, G; Passaro, A; Caselli, E; Manfredini, R.
  • De Giorgi A; COVID-19 Internal Medicine Units (Clinica Medica, Medicina Interna Universitaria, Medicina Ospedaliera 2), Azienda Ospedaliero-Universitaria "S. Anna", Ferrara, Italy. f.fabbian@ospfe.it.
Eur Rev Med Pharmacol Sci ; 24(15): 8219-8225, 2020 08.
Artículo en Inglés | MEDLINE | ID: covidwho-724284
ABSTRACT

OBJECTIVE:

At the end of 2019, the Novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), spread rapidly from China to the whole world. Circadian rhythms can play crucial role in the complex interplay between viruses and organisms, and temporized schedules (chronotherapy) have been positively tested in several medical diseases. We aimed to compare the possible effects of a morning vs. evening antiviral administration in COVID patients. PATIENTS AND

METHODS:

We retrospectively evaluated all patients admitted to COVID internal medicine units with confirmed SARS-CoV-2 infection, and treated with darunavir-ritonavir (single daily dose, for seven days). Age, sex, length of stay (LOS), pharmacological treatment, and timing of antiviral administration (morning or evening), were recorded. Outcome indicators were death or LOS, and laboratory parameters, e.g., variations in C-reactive protein (CRP) levels, ratio of arterial oxygen partial pressure (PaO2, mmHg) to fractional inspired oxygen (FiO2) (PaO2/FiO2), and leucocyte count.

RESULTS:

The total sample consisted of 151 patients, 33 (21.8%) of whom were selected for antiviral treatment. The mean age was 61.8±18.3 years, 17 (51.5%) were male, and the mean LOS was 13.4±8.6 days. Nine patients (27.3%) had their antiviral administration in the morning, and 24 (72.7%) had antiviral administration in the evening. No fatalities occurred. Despite the extremely limited sample size, morning group subjects showed a significant difference in CRP variation, compared to that in evening group subjects (-65.82±33.26 vs. 83.32±304.89, respectively, p<0.032). No significant differences were found for other parameters.

CONCLUSIONS:

This report is the first study evaluating temporized morning vs. evening antiviral administration in SARS-CoV-2 patients. The morning regimen was associated with a significant reduction in CRP values. Further confirmations with larger and multicenter samples of patients could reveal novel potentially useful insights.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Antivirales / Neumonía Viral / Mortalidad Hospitalaria / Infecciones por Coronavirus / Ritonavir / Cronoterapia de Medicamentos / Darunavir / Tiempo de Internación Tipo de estudio: Estudio experimental / Estudio observacional / Estudio pronóstico Límite: Adulto / Anciano / Humanos / Middle aged País/Región como asunto: Europa Idioma: Inglés Revista: Eur Rev Med Pharmacol Sci Asunto de la revista: Farmacología / Toxicología Año: 2020 Tipo del documento: Artículo País de afiliación: Eurrev_202008_22511

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Antivirales / Neumonía Viral / Mortalidad Hospitalaria / Infecciones por Coronavirus / Ritonavir / Cronoterapia de Medicamentos / Darunavir / Tiempo de Internación Tipo de estudio: Estudio experimental / Estudio observacional / Estudio pronóstico Límite: Adulto / Anciano / Humanos / Middle aged País/Región como asunto: Europa Idioma: Inglés Revista: Eur Rev Med Pharmacol Sci Asunto de la revista: Farmacología / Toxicología Año: 2020 Tipo del documento: Artículo País de afiliación: Eurrev_202008_22511